Key terms
About UBX
Unity Biotechnology, Inc. operates as a biotechnology company. The firm is developing a portfolio of programs like biological mechanisms implicated in diseases of aging, and also senolytic programs in ophthalmologic and neurologic disorders. The company was founded by Nathaniel Eames David, Jan van Deursen, Judith Campisi, and Daohong Zhou on March 30, 2009 and is headquartered in South San Francisco, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest UBX news
Apr 16
6:35am ET
Unity Biotechnology price target lowered to $8 from $10 at H.C. Wainwright
Apr 16
6:31am ET
Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)
Apr 15
7:02am ET
Unity Biotechnology reports Q4 EPS (28c), consensus (72c)
Feb 06
8:18am ET
Unity Biotechnology announces new research on potential of Senolytics
No recent press releases are available for UBX
UBX Financials
Key terms
Ad Feedback
UBX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
UBX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
